Table 3.
Clinical trials of NK cells in cancer
| Cancer type | Source | Enrichment of NK cells | Lymphodepletion | Patient (N) | Clinical response |
|---|---|---|---|---|---|
| AML, CML, MDS |
Haploidentical (HSTC donor) |
CD3−CD56+ selection | None | 5 | CR in 4 [141] patients |
| AML | Haploidentical | CD3 depleted PBMCs, IL-2 stimulation | Flu/Cy | 19 | CR in 5 patients [142] |
| AML | Haploidentical | CD3 depleted PBMCs, IL-2 stimulation (n = 32) CD3 depleted PBMCs, CD56 selection, IL-2 stimulation (n = 10) | Flu/Cy | 42 | CR in 9 patients [125] |
| AML | Haploidentical | CD3 depleted PBMCs (with or without CD56 selection), or CD3 and CD19 depleted PBMCs, IL-2 stimulation | 15 | CR in 8 patients [125] | |
| AML | Haploidentical | CD3 and CD19 depleted PBMCs, IL-15 stimulation | Flu/Cy | 40 | CR in 7 patients [143] |
| AML | Umbilical cord blood | Differentiation and expansion from CD34+ cells | Flu/Cy | 10 | CR in 10 patients[144] |
| AML, CML | HSCT donor | CD3 depletion, co-culture with K562-mbIL-21 | HSCT conditioning | 13 | CR in 7 of 8patients with AML and in all 5patients with CML [145] |
| MM | Autologous or haploidentical | Co-culture with K562-mbIL-15-4-1BBL, CD3 depletion | Bortezomib alone or with Flu/Cy and dexamethasone | 7 | Two patients were treatment-free for 6 months [146] |
| B-NHL | Haploidentical | CD3and CD19depleted PBMCs, IL-2 stimulation, pretreatment with rituximab | Flu/Cy, methylprednisolone | 14 |
CR in 2 patients; PR in 2 patients [147] |
| Neuroblastoma | Haploidentical | CD3−CD56+selection, IL-2 stimulation, anti-GD2 after NK cell infusion | Cy, vincristine, and topotecan | 35 |
CR in 5patients; PR in 5patients [148] |
| RCC | Haploidentical | CD3depleted PBMCs, IL-2 stimulation | Flu | 7 | No[142] |
| Melanoma, RCC | Haploidentical | CD3-depleted PBMCs, IL-2 stimulation | Cy and methylprednisolone | 16 | SD in 6patients[142] |
| Ovarian cancer, breast cancer | Haploidentical | CD3-depleted PBMCs | Flu/Cy, TBI (2 Gy) | 20 |
PR in 4patients; SD in 12patients [149] |